Table 1. Clinical characteristics of all patients.
| Total | UST | GUS | SEC | IXE | BRO | ||||||||
| (n = 603) | (n = 256) | (n = 53) | (n = 183) | (n = 39) | (n = 72) | p value | |||||||
| Age (years) | 54.0±16.3 | 53.8±17.1 | 55.0±17.3 | 53.6±15.5 | 55.3±12.9 | 54.3±16.3 | 0.96 | ||||||
| Male (%) | 418 (69.3) | 174 (68.0) | 37 (69.8) | 131 (71.6) | 29 (74.4) | 47 (65.3) | 0.79 | ||||||
| BMI | 23.9±3.9 | 23.4±3.6 | 23.6±3.9 | 23.7±3.8§ | 26.7±4.6 | 24.3±4.6 | <0.0001 | ||||||
| Disease duration (years) | 16.4±11.7 | 15.4±10.8 | 15.1±8.7 | 15.4±11.3 | 20.8±13.8 | 20.4±14.8 | 0.003 | ||||||
| History of smoking (%) | 198 (34.6) | unknown: n = 30 | 78 (31.6) | unknown: n = 9 | 11 (25) | unknown: n = 9 | 65 (36.7) | unknown: n = 6 | 17 (45.9) | unknown: n = 2 | 27 (39.7) | unknown: n = 4 | 0.2 |
| Underlying IP(%) | 18 (3.0) | 7 (2.7) | 1 (1.9) | 6(3.3) | 1 (2.6) | 3(4.2) | 0.95 | ||||||
| Type of psoriasis | 0.005 | ||||||||||||
| PsV | 523 | (86.7%) | 237 | (92.6%) | 47 | (88.7%) | 148 | (80.9%) | 30 | (76.9%) | 63 | (87.5%) | |
| PsA | 61 | (10.1%) | 13 | (5.1%) | 3 | (5.7%) | 30 | (16.4%) | 8 | (20.5%) | 7 | (9.7%) | |
| GPP | 8 | (1.3%) | 1 | (0.4%) | 0 | (0%) | 4 | (2.2%) | 1 | (2.6%) | 2 | (2.8%) | |
| PsE | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | |
| PsG | 1 | (0.2%) | 1 | (0.4%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | |
| PPP | 7 | (1.2%) | 3 | (1.2%) | 3 | (5.7%) | 1 | (0.5%) | 0 | (0%) | 0 | (0%) | |
| others | 1 | (0.5%) | 1 | (0.4%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | |
| Treatment period (months) | 21.1±21.3 | 31.5±26.6 | 4.0±4.0 | 18.5±12.3 | 7.2±5.6 | 11.0±7.4 | <0.0001 | ||||||
| biologic treatment | |||||||||||||
| UST | 256 | (42.5%) | |||||||||||
| GUS | 53 | (8.8%) | |||||||||||
| SEC | 183 | (30.3%) | |||||||||||
| IXE | 39 | (6.5%) | |||||||||||
| BRO | 72 | (11.9%) | |||||||||||
| Prior biologic treatment | |||||||||||||
| IFX | 41 | (6.8%) | 18 | (7.0%) | 1 | (1.9%) | 17 | (9.3%) | 3 | (7.7%) | 2 | (2.8%) | <0.0001 |
| ADA | 78 | (12.9%) | 25 | (9.8%) | 3 | (5.7%) | 41 | (22.4%) | 5 | (12.8%) | 4 | (5.6%) | |
| UST | 59 | (9.8%) | 0 | (0%) | 12 | (22.6%) | 41 | (22.4%) | 0 | (0%) | 6 | (8.3%) | |
| GUS | 1 | (0.2%) | 0 | (0%) | 0 | (0%) | 1 | (0.5%) | 0 | (0%) | 0 | (0%) | |
| SEC | 50 | (8.3%) | 4 | (1.56%) | 9 | (17.0%) | 0 | (0%) | 8 | (20.5%) | 29 | (40.3%) | |
| IXE | 3 | (0.5%) | 0 | (0%) | 1 | (1.9%) | 1 | (0.5%) | 0 | (0%) | 1 | (1.39%) | |
| BRO | 12 | (2.0%) | 0 | (0%) | 2 | (3.8%) | 3 | (1.6%) | 7 | (17.9%) | 0 | (0%) | |
| Total | 244 | (40.5%) | 47 | (18.4%) | 28 | (52.8%) | 104 | (56.8%) | 23 | (59.0%) | 42 | (58.3%) | |
| KL-6 (U/mL) | 283.8±247.9 | 271.8±206.1 | 290.7±227.6 | 284.1±303.5 | 302.7±172.5 | 292.8±216.1 | 0.95 | ||||||
| DIIP | 6 | (1.0%) | 3 | (1.16%) | 1 | (1.89%) | 2 | (1.09%) | 0 | (0%) | 0 | (0%) | 0.95 |
UST: Ustekinumab, GUS: Guselkumab, SEC: Secukinumab, IXE: Ixekizumab, BRO: Brodalumab, IFX: infliximab, ADA: Adalimumab.
IP: Interstitial pneumonia, DILI: Drug-induced lung injury.
KL-6: Krebs von den lungen-6, PsV: Psoriasis vulgaris, PsA: Psoriatic arthritis, GPP: Generalized pustular psoriasis, PsE: Erythrodermic psoriasis, PsG: Guttate psoriasis, PPP: Palmoplantar pustulosis.